Acute versus chronic arsenic poisoning

View at publisher
Authors: Hung-Kai Lo, Szu-Chi Chen, Po-Jen Hsiao
Cited by: 0
References: 3

Abstract

Dear Editor, We would like to comment on the recent publication ‘Chronic arsenic poisoning’ by Run Dong and Yang Jiao. Common sources of arsenic exposure include contaminated groundwater, seafood containing organic arsenic, traditional or herbal remedies, occupational exposure in smelting and pesticide manufacturing, and burning of arsenic-rich coal. The authors provide a clear overview of the characteristic clinical spectrum of chronic arsenic toxicity, particularly highlighting cutaneous changes, peripheral neuropathy and hepatic dysfunction, features that often offer essential diagnostic clues in long-standing exposure.1 The text may be further strengthened by briefly expanding on several practical aspects. Early dermatologic signs, such as hyperpigmentation in acute exposure, and hypopigmentation including the ‘raindrop’ pattern in chronic arsenic exposure, could be described in slightly greater detail to help clinicians recognize pathognomonic features.2 In addition to blood testing, urine, hair and nail analyses can be performed to evaluate arsenic exposure. Comprehensively, urinary arsenic, particularly in a 24-h collection, remains the most reliable indicator of recent exposure, whereas hair and nail analyses help identify chronic accumulation over weeks to months. Unlike blood tests, which mainly reflect very recent exposure due to the short half-life of arsenic in circulation, these specimens provide a broader temporal picture of exposure. It is also important to note that chronic arsenic exposure is carcinogenic, associated with skin, lung, bladder and kidney cancer.3 Differential diagnoses include chronic liver disease, metabolic pigment disorders, autoimmune diseases, nutritional deficiencies, other heavy metal toxicities and myelodysplastic syndromes should also be considered. The main management of arsenic exposure includes removal of the exposure source and chelation therapy when indicated (dimercaprol, dimercaptosuccinic acid or 2,3-dimercapto-1-propanesulfonic acid), as timely intervention significantly improves outcomes. We appreciate the contribution of Run Dong and Yang Jiao and hope these thoughts further complement their work.

Fields of Study & Subjects

Heavy Metal Exposure and Toxicity Arsenic contamination and mitigation Poisoning and overdose treatments

Publication details

Journal / source
QJM
Publication date
12 January 2026
Language
EN